A stroke occurs when the blood flow to the brain is suddenly interrupted, depriving brain cells of oxygen and glucose and leading to further cell death. Neuroimaging techniques, such as computed tomography and magnetic resonance imaging, have greatly improved our ability to visualise brain structures and are routinely used to diagnose the affected vascular region of a stroke patient's brain and to inform decisions about clinical care. Currently, these multimodal imaging techniques are the backbone of the clinical management of stroke patients and have immensely improved our ability to visualise brain structures. Here, we review recent developments in the field of neuroimaging and discuss how different imaging techniques are used in the diagnosis, prognosis and treatment of stroke.
Over 17 million people experience a stroke episode annually, with 5.9 million deaths. Stroke is diagnosed by physical tests and neuroimaging which need to be performed quickly to determine if the stroke is caused by ischaemia or haemorrhage. Neuroimaging can reliably confirm bleeding, but many patients with suspected ischaemic stroke (up to 40%) are subsequently confirmed to have alternative pathologies e.g., migraine or seizures (stroke mimics) delaying the transfer of stroke patients to an acute stroke unit for early intervention and treatment. Thus, a simple complimentary blood biomarker test to differentiate stroke patients from non-stroke patients with similar clinical symptoms is essential in prehospital and emergency settings for efficient stroke management and prompt treatment. The current 'Gold Standard' technique for detecting protein biomarkers is complex, time-consuming, and requires automated equipment. In this study, we have developed a proof-of-concept of lanthanide-doped upconversion nanoparticle (UCNP)-based optical biosensor platform for detecting glial fibrillary acidic protein (GFAP), a potential stroke biomarker, in human blood serum. The results show a linear response in photoluminescence quenching of UCNP conjugated GFAP antibody with the increasing concentration of GFAP biomarker in human blood serum. This approach can be used in the ambulance and Emergency Department to quickly diagnose a stroke. In the longer term, such techniques can be integrated into a self-assessment kit to monitor those patients who are at risk after strokes.
3 December 2019 in Journal of Physics G: Nuclear and Particle Physics
Excited states of 127 Xe were populated in the 122 Sn( 9 Be, 4n γ ) fusion-evaporation reaction at a beam energy of 48 MeV. A sequence of Δ I = 2 γ -transitions has been observed above the Iπ = 19/2 + state at 2307 keV. Spin and parity of the states belonging to this band have been assigned firmly. The dynamic moment of inertia of this band is found to be low and almost constant as a function of angular momentum. Observed experimental features along with the results of theoretical semiclassical model calculation suggest an antimagnetic rotational character for this band.
The level scheme of is extended up to 55/2 and 4.8 MeV excitation energy with the addition of 52 new -ray transitions. Previously established isomers and their half-lives, except for the state, are revisited. The discrepancy in the half-life of the state is resolved, and its half-life is revised to 11.4(14) ns. An overall good agreement is observed between the experimental results and the shell-model calculations performed using the CD-Bonn interaction derived from the renormalization approach. A weak coupling of the odd proton to the even-even core is observed to account for the level structure at lower energies, which strongly resembles a decoupled nonrotational band. A new positive-parity sequence is also established which is observed to originate from the coupling of the proton at low excitation energy.
Background: Stroke is one of the leading causes of death and disability worldwide. The diagnosis of stroke remains largely clinical, yet widely used stroke scoring systems and brain imaging do not satisfactorily allow the distinction of ischaemic stroke (IS) patients from stroke mimics (SMs). Blood biomarkers are promising tools that could facilitate clinical triage. Methods: This study recruited 66 patients with IS and 24 SMs. The levels of Glial fibrillary acidic protein (GFAP), Neuron-specific enolase (NSE), Neurofilament light chain (NfL) and blood-brain barrier (BBB) proteins [Occludin (OCLN), Zonula occludens 1 (ZO-1), Claudin-5] in blood serum were measured by enzyme-linked immunosorbent assay technique. Biomarker levels in IS patients and SMs were compared using the Mann–Whitney U test. Multivariable logistic regression analysis was used to evaluate the diagnostic performance of biomarkers in combination with the National Institutes of Health Stroke Scale (NIHSS) score. Results: More significant differences in circulating GFAP, NfL, OCLN, ZO-1, and Claudin-5 but not NSE were found in IS patients compared to SMs. A combination of circulating ZO-1, Claudin-5, and OCLN with NIHSS score gives the highest diagnostic accuracy, sensitivity, and specificity. Conclusions: A prediction model with circulating BBB proteins in combination with NIHSS score differentiates between IS patients and SMs.
11 February 2020 in The European Physical Journal A